Giuseppe Porcellini1, Giovanni Merolla2, Nicola Giordan3, Paolo Paladini1, Andrea Burini3, Eugenio Cesari4, Alessandro Castagna4. 1. Unit of Shoulder and Elbow Surgery, D. Cervesi Hospital, Cattolica (RN), AUSL della Romagna Ambito Rimini, Italy. 2. Unit of Shoulder and Elbow Surgery, D. Cervesi Hospital, Cattolica (RN), AUSL della Romagna Ambito Rimini, Italy; "Marco Simoncelli" Biomechanics Laboratory D. Cervesi Hospital, Cattolica (RN), AUSL della Romagna Ambito Rimini, Italy. 3. Research and Development Department - Fidia Farmaceutici SpA, Abano Terme (PD), Italy. 4. Unit of Orthopaedics, Istituto Clinico Humanitas, Rozzano (MI), Italy.
Abstract
PURPOSE: numerous experimental and clinical studies in osteoarthritis (OA) have demonstrated that intra-articular (IA) administration of hyaluronic acid can improve the altered rheological properties of the synovial fluid and exert protective and reparative effects on the joint structure. The objective of this study was to evaluate the safety and performance of HYADD®4-G (Hymovis®) in patients with glenohumeral joint OA. METHODS: forty-one patients with shoulder pain and limited shoulder function resulting from concentric glenohumeral joint OA were enrolled in a multicenter clinical trial. Patients received two HYADD®4-G injections administered one week apart. The main outcome measure was improvement in shoulder pain on movement at six months as assessed through a 100-mm visual analog scale (VAS), range of motion (ROM) values, and Constant-Murley Shoulder Outcome Score (CS). RESULTS: two IA injections of HYADD®4-G (Hymovis®) significantly decreased pain and improved shoulder function for up to six months from the first injection. The VAS score decreased (from 66.1 mm to 37.7 mm at six months) and improvements were recorded in the total CS and in the ROM values ( rotation decreased from a mean value of 54.2° at baseline to 63.2° at six months and internal rotation from a mean value of 44.0° at baseline to 45.7° at 26 weeks). No serious adverse events occurred. CONCLUSIONS: the study results demonstrated that two IA injections of HYADD®4-G (Hymovis®) may be a safe and effective treatment option for shoulder pain associated with glenohumeral OA and that the effects of the injections are still present for up to six months after the treatment. LEVEL OF EVIDENCE: Level IV, therapeutic case series.
PURPOSE: numerous experimental and clinical studies in osteoarthritis (OA) have demonstrated that intra-articular (IA) administration of hyaluronic acid can improve the altered rheological properties of the synovial fluid and exert protective and reparative effects on the joint structure. The objective of this study was to evaluate the safety and performance of HYADD®4-G (Hymovis®) in patients with glenohumeral joint OA. METHODS: forty-one patients with shoulder pain and limited shoulder function resulting from concentric glenohumeral joint OA were enrolled in a multicenter clinical trial. Patients received two HYADD®4-G injections administered one week apart. The main outcome measure was improvement in shoulder pain on movement at six months as assessed through a 100-mm visual analog scale (VAS), range of motion (ROM) values, and Constant-Murley Shoulder Outcome Score (CS). RESULTS: two IA injections of HYADD®4-G (Hymovis®) significantly decreased pain and improved shoulder function for up to six months from the first injection. The VAS score decreased (from 66.1 mm to 37.7 mm at six months) and improvements were recorded in the total CS and in the ROM values ( rotation decreased from a mean value of 54.2° at baseline to 63.2° at six months and internal rotation from a mean value of 44.0° at baseline to 45.7° at 26 weeks). No serious adverse events occurred. CONCLUSIONS: the study results demonstrated that two IA injections of HYADD®4-G (Hymovis®) may be a safe and effective treatment option for shoulder pain associated with glenohumeral OA and that the effects of the injections are still present for up to six months after the treatment. LEVEL OF EVIDENCE: Level IV, therapeutic case series.
Authors: V Listrat; X Ayral; F Patarnello; J P Bonvarlet; J Simonnet; B Amor; M Dougados Journal: Osteoarthritis Cartilage Date: 1997-05 Impact factor: 6.576
Authors: Theodore Blaine; Roland Moskowitz; James Udell; Michael Skyhar; Robert Levin; Jeffrey Friedlander; Michael Daley; Roy Altman Journal: J Bone Joint Surg Am Date: 2008-05 Impact factor: 5.284
Authors: Jonathan S Kirschner; Jennifer Cheng; Andrew Creighton; Kristen Santiago; Nicole Hurwitz; Mark Dundas; Nicholas Beatty; Dallas Kingsbury; Gabrielle Konin; Zafir Abutalib; Richard Chang Journal: Clin J Sport Med Date: 2022-03-17 Impact factor: 3.454
Authors: Simone Tortato; Alberto DE Castro Pochini; Carlos Vicente Andreoli; Carina Cohen; Paulo Henrique Schmidt Lara; Paulo Santoro Belangero; Benno Ejnisman Journal: Acta Ortop Bras Date: 2022-01-28 Impact factor: 0.513